866-997-4948(US-Canada Toll Free)

Diabetic Peripheral Neuropathy - Pipeline Review, H1 2015

Published By :

Global Markets Direct

Published Date : Jan 2015

Category :

Diabetes

No. of Pages : 50 Pages


Global Markets Directs, Diabetic Peripheral Neuropathy Pipeline Review, H1 2015, provides an overview of the Diabetic Peripheral Neuropathys therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Diabetic Peripheral Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Peripheral Neuropathy and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Diabetic Peripheral Neuropathy
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Diabetic Peripheral Neuropathy and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Diabetic Peripheral Neuropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Diabetic Peripheral Neuropathy pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Diabetic Peripheral Neuropathy
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Diabetic Peripheral Neuropathy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents 2
List of Tables 4
List of Figures 4

Introduction 5
Global Markets Direct Report Coverage 5
Diabetic Peripheral Neuropathy Overview 6
Therapeutics Development 7
Pipeline Products for Diabetic Peripheral Neuropathy - Overview 7
Pipeline Products for Diabetic Peripheral Neuropathy - Comparative Analysis 8
Diabetic Peripheral Neuropathy - Therapeutics under Development by Companies 9
Diabetic Peripheral Neuropathy - Therapeutics under Investigation by Universities/Institutes 10
Diabetic Peripheral Neuropathy - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Diabetic Peripheral Neuropathy - Products under Development by Companies 13
Diabetic Peripheral Neuropathy - Products under Investigation by Universities/Institutes 14
Diabetic Peripheral Neuropathy - Companies Involved in Therapeutics Development 15
Astellas Pharma Inc. 15
BioChemics, Inc. 16
Cebix Incorporated 17
Pfizer Inc. 18
ViroMed Co., Ltd. 19
Diabetic Peripheral Neuropathy - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
Antimunocel - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ASP-8477 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
benfotiamine - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
CBX-129801 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
CNV-2197944 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
epalrestat - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
PF-05089771 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
VM-202 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Diabetic Peripheral Neuropathy - Recent Pipeline Updates 43
Diabetic Peripheral Neuropathy - Dormant Projects 46
Diabetic Peripheral Neuropathy - Discontinued Products 47
Diabetic Peripheral Neuropathy - Product Development Milestones 48
Featured News & Press Releases 48
Jun 09, 2012: Cebix's Ersatta Demonstrates Encouraging Results In Phase I Study Of Diabetic Peripheral Neuropathy 48

Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 50
Disclaimer 50

List of Table


Number of Products under Development for Diabetic Peripheral Neuropathy, H1 2015 7
Number of Products under Development for Diabetic Peripheral Neuropathy - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Products under Investigation by Universities/Institutes, H1 2015 14
Diabetic Peripheral Neuropathy - Pipeline by Astellas Pharma Inc., H1 2015 15
Diabetic Peripheral Neuropathy - Pipeline by BioChemics, Inc., H1 2015 16
Diabetic Peripheral Neuropathy - Pipeline by Cebix Incorporated, H1 2015 17
Diabetic Peripheral Neuropathy - Pipeline by Pfizer Inc., H1 2015 18
Diabetic Peripheral Neuropathy - Pipeline by ViroMed Co., Ltd., H1 2015 19
Assessment by Monotherapy Products, H1 2015 20
Number of Products by Stage and Target, H1 2015 22
Number of Products by Stage and Mechanism of Action, H1 2015 24
Number of Products by Stage and Route of Administration, H1 2015 26
Number of Products by Stage and Molecule Type, H1 2015 28
Diabetic Peripheral Neuropathy Therapeutics - Recent Pipeline Updates, H1 2015 43
Diabetic Peripheral Neuropathy - Dormant Projects, H1 2015 46
Diabetic Peripheral Neuropathy - Discontinued Products, H1 2015 47

List of Chart


Number of Products under Development for Diabetic Peripheral Neuropathy, H1 2015 7
Number of Products under Development for Diabetic Peripheral Neuropathy - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Products, H1 2015 12
Assessment by Monotherapy Products, H1 2015 20
Number of Products by Top 10 Targets, H1 2015 21
Number of Products by Stage and Top 10 Targets, H1 2015 22
Number of Products by Top 10 Mechanism of Actions, H1 2015 23
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 24
Number of Products by Top 10 Routes of Administration, H1 2015 25
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 26
Number of Products by Top 10 Molecule Types, H1 2015 27
Number of Products by Stage and Top 10 Molecule Types, H1 2015 28

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *